Search | Clinical Trials Finder

Conditions: Major Depressive Disorder
Interventions: Placebo, Brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more

Conditions: Binge Eating, Depression
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Major Depressive Disorder
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Garden Grove, California • National City, California • Oceanside, California + 34 more

Conditions: Parkinson's Disease
Interventions: Duloxetine, Donepezil, Modafinil; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression
Interventions: Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more

Conditions: Knee Osteoarthritis
Interventions: Duloxetine, Celecoxib, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 41 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Generalized Anxiety Disorder
Interventions: Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 36
States / cities: Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more

Conditions: Depressive Disorder, Major
Interventions: SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 51
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more

Conditions: Major Depressive Disorder
Interventions: duloxetine vs. escitalopram; Drug
Lead sponsor: Duke University; Other
Eligibility: 20 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more

Conditions: Pain
Interventions: Duloxetine; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 25 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Salt Lake City, Utah

Conditions: Anxiety Disorders
Interventions: Duloxetine, venlafaxine, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 19
States / cities: Birmingham, Alabama • La Mesa, California • Denver, Colorado + 16 more

Conditions: Major Depressive Disorder, Back Pain, Aged
Interventions: Duloxetine; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 25 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 475
States / cities: Antioch, California • Berkeley, California • Burlingame, California + 328 more

Conditions: Fibromyalgia
Interventions: Duloxetine, Skin biopsy; Drug · Procedure
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Albany, New York

Conditions: Major Depressive Disorder
Interventions: duloxetine hydrochloride, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 65 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 23
States / cities: Pasadena, California • Sherman Oaks, California • Hamden, Connecticut + 20 more

Conditions: Depression, Pain
Interventions: Duloxetine Hydrochloride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 25
States / cities: Peoria, Arizona • Burbank, California • Fresno, California + 22 more

Conditions: Irritable Bowel Syndrome
Interventions: duloxetine; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Quality of Recovery, Gynecologic Surgery, Laparoscopy
Interventions: duloxetine, placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder
Interventions: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 36
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more

Conditions: Major Depressive Disorder
Interventions: duloxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 22
States / cities: Dothan, Alabama • Chandler, Arizona • El Centro, California + 19 more

Conditions: Mild Cognitive Impairment, Depression
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 50 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Fatigue Syndrome, Chronic
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Study to Assess Mechanisms in Peripheral Tissue Innervation for Fibromyalgia

A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients

Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain

An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome

Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder

The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment

Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome